Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
European Urology|October 6, 2012
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinomaA Ari Hakimi, Ying-Bei Chen, James Wren, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Cancer|October 28, 2015
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinomaA Ari Hakimi, Irina Ostrovnaya, Anders Jacobsen, et al.
Urologic Oncology|November 15, 2017
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutationsBrandon J Manley, Ed Reznik, Mazyar Ghanaat, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
European Urology|October 6, 2012
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinomaA Ari Hakimi, Ying-Bei Chen, James Wren, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Cancer|October 28, 2015
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinomaA Ari Hakimi, Irina Ostrovnaya, Anders Jacobsen, et al.
Urologic Oncology|November 15, 2017
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutationsBrandon J Manley, Ed Reznik, Mazyar Ghanaat, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 15